Topic: Generic Drugs

JD Supra Corporate Brief: Social Media, Virtual Currencies, Patent Trolls, Generic Drugs

On this day in 1974, the Department of Justice filed its final antitrust suit against the AT&T Corporation, leading to the breakup of AT&T and its Bell System. Have a social media policy? You’ll want to add these items… (JD Supra Perspectives) Sure, Bitcoins and other virtual currencies present tantalizing investment opportunities, but look before… Read more »

FDA’s Proposed Rule on Generic Drug Labeling Could Sow Confusion and Chaos (and Lawsuits)

The FDA wants to give generic drug makers the same labeling authority as their branded peers. Attorneys Erin Bosman, James Huston, and Julie Park of Morrison & Foerster explain: [T]he U.S. Food and Drug Administration (FDA) published a long-awaited proposed rule … in an effort to ‘create parity’ between brand-name and generic manufacturers for their… Read more »

JD Supra Corporate Brief: Shareholder Activism, Google Filters, Disappearing Goodwill, Fair Lending

Slow morning? Let the JD Supra Corporate Brief jumpstart your day: Public corporations aren’t the only ones who have to worry about shareholder activism – so do the country’s banks… (Skadden Arps) The law may be on his side, but erasing compromising photos of Max Mosley on the Internet will take more than a filter… Read more »

JD Supra Corporate Brief: Abusive Practices, Illegal Subsidies, Credit Ratings, Patent Trolls, I-9 Data

Long week? Kick back with the JD Supra Corporate Brief. You’ll feel better… The CFPB just took action against a debt collector for “abusive practices.” And the entire debt-collection industry should sit up and take notice (Foley & Lardner) You can relax now: NASDAQ is withdrawing its proposal to require listed companies maintain an internal… Read more »